Skip to Content
Merck
CN
All Photos(1)

Documents

475889

Sigma-Aldrich

MK-886

A cell-permeable, orally active NSAID that blocks cellular Cox pathway PGE2 production by inhibiting COX-1 and mPGES-1, but not COX-2, activity, as well as suppresses cellular 5-LO pathway activation by inhibiting FLAP, rather than 5-LO, activity.

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
MK-886, 3-[1-( p-Chlorobenzyl)-5-(isopropyl)-3- t-butylthioindol-2-yl]-2,2-dimethylpropanoic Acid, Na, COX-1 Inhibitor III, FLAP Inhibitor I, MK886, mPGES-1 Inhibitor I
Empirical Formula (Hill Notation):
C27H33ClNO2S · Na
CAS Number:
118414-82-7
Molecular Weight:
494.06
UNSPSC Code:
51111800
NACRES:
NA.77

Quality Level

100

Assay

≥99% (TLC)

form

solid

potency

102 nM IC50

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

color

white

solubility

DMSO: 25 mg/mL
ethanol: 25 mg/mL

shipped in

ambient

storage temp.

10-30°C

InChI

1S/C27H34ClNO2S/c1-6-7-14-32-25-22-15-20(18(2)3)10-13-23(22)29(17-19-8-11-21(28)12-9-19)24(25)16-27(4,5)26(30)31/h8-13,15,18H,6-7,14,16-17H2,1-5H3,(H,30,31)

InChI key

VFMGWQLOCZBFCK-UHFFFAOYSA-N

General description

A cell-permeable, orally active NSAID (nonsteroidal antiinflammatory drug) that blocks cellular Cox pathway PGE2 (prostaglandin E2) production by inhibiting COX-1 and mPGES-1 (microsomal PGE2 synthase-1), but not COX-2, activity (IC50 = 8, 2, and 58 M, respectively), as well as suppresses cellular 5-LO (5-Lypoxygenase; Cat. No. 437996) pathway activation by inhibiting FLAP (5-LO-activating protein), rather than 5-LO, activity (<10% by 1 M MK-886). Unlike NSAIDs (nonsteroidal antiinflammatory drugs) that target only COX pathway, MK-886 does not cause gastrointestinal damages when applied in vivo.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
leukotreine biosybthesis
Product does not compete with ATP.
Reversible: no

Warning

Toxicity: Standard Handling (A)

Other Notes

Koeberle, A., et al. 2009. Eur. J. Pharmacol.608, 84.
Koeberle, A., et al. 2008. J. Pharmacol. Exp. Ther.326, 975.
Fisher, L., et al. 2007. Br. J. Pharmacol.152, 471.
Ford-Hutchinson, A.W., et al. 1993. Can. J. Physiol. Pharmacol. 71, 806.
Ford-Hutchinson, A.W. 1991. Trends Pharmacol.12, 68.
Dixon, R.A., et al. 1990. Nature 343, 282.
Rouzer, C.A., et al. 1990. J. Biol. Chem.265, 1436.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ichitaro Abe et al.
Developmental cell, 57(23), 2623-2637 (2022-12-07)
De novo beige adipocyte biogenesis involves the proliferation of progenitor cells in white adipose tissue (WAT); however, what regulates this process remains unclear. Here, we report that in mouse models but also in human tissues, WAT lipolysis-derived linoleic acid triggers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service